Carl Icahn shares common ground with the FTC, which argued that Illumina’s acquisition of cancer test developer Grail would stifle competition and innovation.
Carl Icahn claims Illumina directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of Grail
A fight has broken out between veteran activist Carl Icahn and biotech company Illumina as the investor nominates three candidates to the board.
Veteran activist Carl Icahn took an 8.5% stake in Crown Holdings. There are a few opportunities to build shareholder value.